Immutep, 3rd Annual Advances in Immuno-oncology Congress Presentation | Finance News Network

Media ReleasesImmutep

View All Immutep News


Immutep, 3rd Annual Advances in Immuno-oncology Congress Presentation

Two ACTive Immunotherapies In Melanoma (TACTI-mel): Results Of A Phase I

Trial With Metastatic Melanoma Patients Treated With A Soluble LAG-3 Receptor

(LAG-3lg Or Eftilagimod Alpha) As An Antigen Presenting (APC) Activator Combined With Pembrolizumab

Fre´de´ric Triebel MD, PhD

Third Annual Advances in Immuno-oncology Congress

London, May 25, 2018


To view Presentation please download PDF attached: 
Download this document